| Literature DB >> 34747311 |
Xiaoyan Li1,2, Rong Hu1,3, Xinyi Ren1,4, Jie He1,4.
Abstract
Interleukin (IL)-8 has been shown to play an important role in obstructive sleep apnea syndrome (OSAS). However, its role in OSAS development is still controversial. This meta-analysis was to explore the correlation between interleukin (IL)-8 concentration and OSAS. Database (from the inception to July 2021) searches on PubMed, Web of Science, Medline, EMBASE, and Cochrane Library were conducted for studies analyzing the correlation between IL-8 concentration and OSAS, regardless of the language of publication. Standardized mean difference (SMD) and 95% confidence intervals (CI) were used to analyze any prospective association between IL-8 concentration and OSAS. A total of 25 eligible studies, including 2301 participants and 1123 controls, were included in this meta-analysis. The included studies evaluating the association between serum IL-8 concentration and OSAS indicated that adults and children with OSAS had elevated serum concentrations of IL-8 compared with controls (SMD = 0.997, 95% CI = 0.437-1.517, P < 0.001; SMD = 0.431, 95% CI = 0.104-0.759, P = 0.01). Categorization of the study population into subgroups according to body mass index, apnea-hypopnea index (AHI), ethnicity, and sample size also showed that individuals with OSAS had elevated serum concentrations of IL-8 compared with controls. Additionally, the results demonstrated that the higher the AHI, higher was the IL-8 concentration. Similar results were observed in the literature on the association between plasma IL-8 concentration and OSAS. This meta-analysis verified that compared with controls, children and adults with OSAS have significantly elevated IL-8 concentrations.Entities:
Keywords: Obstructive sleep apnea syndrome; interleukin-8; meta-analysis; plasma; serum
Mesh:
Substances:
Year: 2021 PMID: 34747311 PMCID: PMC8809978 DOI: 10.1080/21655979.2021.2001203
Source DB: PubMed Journal: Bioengineered ISSN: 2165-5979 Impact factor: 3.269
Figure 1.Flow diagram of literature selecting process and results
Characteristics of studies included in the meta-analysis
| Author, year | Country | Ethnicity | Ages (mean± SD) | BMI (kg/m2) | AHI(events/h) | n | Sample | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OSA | Control | OSA | Control | OSA | Control | OSA | Control | ||||
| Ohga E [ | Japan | Asian | 47.8 ± 2.2 | 48.9 ± 2.9 | 29.4 ± 1.4 | 28.4 ± 1.4 | 38.9 ± 3.1 | 3.1 ± 0.4 | 20 | 10 | Serum |
| Alzoghaibi [ | Saudi Arabia | Caucasian | 49.5 ± 2.2 | 30.7 ± 1.5 | 36.3 ± 1.5 | 23.4 ± 0.7 | 73.5 ± 6.9 | NA | 25 | 17 | Serum |
| Ryan S(mild to moderate), [ | Ireland | Caucasian | 42 ± 8 | 41 ± 8 | 32.9 ± 6.03 | 30.7 ± 3.1 | 15.9 ± 7.7 | 1.2 ± 1.0 | 35 | 30 | Serum |
| Ryan S(severe) [ | Ireland | Caucasian | 43 ± 9 | 41 ± 8 | 32.1 ± 3.5 | 30.7 ± 3.1 | 56.6 ± 20.9 | 1.2 ± 1.0 | 31 | 30 | Serum |
| Devouassoux G [ | France | Caucasian | 54 ± 11 | 45 ± 7 | 28.7 ± 5.4 | 18.2 ± 3.7 | NA | NA | 57 | 13 | Sputum |
| Borel JC [ | France | Caucasian | 57 ± 10 | 56 ± 10 | 41.0 ± 5.2 | 40.9 ± 5.1 | 57 ± 54 | NA | 14 | 39 | Serum |
| Carpagnano GE(obesity) [ | Italy | Caucasian | 47.3 ± 13.2 | 45.9 ± 9.9 | 42.6 ± 6.8 | 34.5 ± 5.5 | 48.8 ± 23.1 | 3.9 ± 1.0 | 12 | 10 | Plasma |
| Carpagnano GE(non-obesity) [ | Italy | Caucasian | 53.9 ± 11.8 | 42 ± 4 | 25.9 ± 1.5 | 24.6 ± 2.6 | 37.5.04 ± 11.8 | 3.2 ± 0.9 | 10 | 8 | Plasma |
| Kim J(moderate) [ | Korea | Asian | 38 ± 15.04 | 26 ± 6.91 | 24.43 ± 2.45 | 23.88 ± 2.3 | 14.4 ± 4.07 | 1.25 ± 1.25 | 9 | 22 | Serum |
| Kim J(severe), [ | Korea | Asian | 42 ± 10.77 | 26 ± 6.91 | 28.69 ± 4.05 | 23.88 ± 2.3 | 52.71 ± 22.23 | 1.25 ± 1.25 | 28 | 22 | Serum |
| Bouloukaki I [ | Greece | Caucasian | 48.5 ± 8.55 | 47.9 ± 7.9 | 32.4 ± 3.74 | 32.6 ± 3.21 | 48.09 ± 26.39 | NA | 31 | 15 | Serum |
| Wang Y [ | China | Asian | 58.6 ± 5.9 | 60.5 ± 5.2 | 31.4 ± 2.1 | 30.4 ± 2.1 | 34.04 ± 14.76 | 1.74 ± 1.48 | 47 | 28 | BAL fluid |
| Thunstrom E(non-obesity) [ | Sweden | Caucasian | 65.3 ± 7.1 | 61.4 ± 9.5 | 26.8 ± 2.1 | 25.2 ± 2.5 | 28.9 ± 13.7 | 3.1 ± 1.3 | 234 | 95 | Serum |
| Thunstrom E(obesity) [ | Sweden | Caucasian | 62.9 ± 8.6 | 61.4 ± 9.5 | 33.5 ± 3.3 | 25.2 ± 2.5 | 31.5 ± 16.2 | 3.1 ± 1.3 | 110 | 95 | Serum |
| Archontogeorgis K [ | Greece | Caucasian | 51.78 ± 11.55 | 51.40 ± 16.24 | 36.34 ± 13.18 | 33.73 ± 5.68 | 28.6 ± 11.2 | NA | 64 | 20 | Serum |
| Taillé C [ | France | Caucasian | 51.2 ± 2.5 | 44.6 ± 2.2 | 29.6 ± 1.4 | 27.2 ± 0.8 | 14.2 ± 1.6 | 2.0 ± 0.2 | 14 | 11 | Sputum |
| Vicente E [ | Spain | Caucasian | 45.41 ± 15.07 | 45.07 ± 11.77 | 30.08 ± 5.12 | 28.08 ± 4.63 | 28.12 ± 24.11 | NA | 89 | 26 | Plasma/ pharyngeal lavage |
| Jin F [ | China | Asian | 55.28 ± 7.13 | 56.13 ± 6.21 | 26.75 ± 3.50 | 25.19 ± 2.44 | 38.01 ± 8.04 | 3.62 ± 1.54 | 100 | 50 | Serum |
| Santamaria-Martos F(mild) [ | Spain | Caucasian | 57.59 ± 16.52 | 44.42 ± 11.39 | 28.05 ± 4.28 | 24.88 ± 3.22 | 9.35 ± 3.75 | 1.88 ± 1.73 | 109 | 132 | Serum |
| Santamaria-Martos F(moderate to severe), [ | Spain | Caucasian | 65.06 ± 12.38 | 44.42 ± 11.39 | 28.68 ± 3.97 | 24.88 ± 3.22 | 28.75 ± 15.68 | 1.88 ± 1.73 | 119 | 132 | Serum |
| Ming H [ | China | Asian | 51.34 ± 5.16 | 52.18 ± 4.51 | 27.01 ± 1.04 | 26.88 ± 1.12 | 31.15 ± 9.12 | 4.34 ± 2.01 | 684 | 192 | Serum |
| Zhang D [ | China | Asian | 40.39 ± 9.58 | 37.73 ± 10.52 | 27.73 ± 2.93 | 24.41 ± 2.86 | 33.24 ± 32.65 | 1.16 ± 0.92 | 21 | 10 | Nasal lavage |
| Bhatt SP [ | India | Asian | 10.71 ± 3.0 | 11.87 ± 2.66 | 27.1 ± 6.53 | 27.40 ± 4.88 | 8.45 ± 10.82 | 0.68 ± 1.13 | 190 | 57 | Serum |
| Bilal N(mild) [ | Turkey | Caucasian | 42.7 ± 14.25 | 42.53 ± 9.81 | 30.65 ± 6.98 | 29.09 ± 4.52 | 9.70 ± 2.77 | 2.62 ± 1.34 | 10 | 30 | Serum |
| Bilal N(moderate) [ | Turkey | Caucasian | 47 ± 9.63 | 42.53 ± 9.81 | 30.66 ± 7.76 | 29.09 ± 4.52 | 20.24 ± 4.40 | 2.62 ± 1.34 | 10 | 30 | Serum |
| Bilal N(severe) [ | Turkey | Caucasian | 43 ± 7.42 | 42.53 ± 9.81 | 29.93 ± 3.71 | 29.09 ± 4.52 | 44.01 ± 10.07 | 2.62 ± 1.34 | 10 | 30 | Serum |
| Tam CS [ | Australia | Caucasian | 7.3 ± 3.7 | 7.6 ± 4 | 19.4 ± 5.5 | 17.9 ± 3.9 | 3.6 ± 3.4 | NA | 44 | 69 | Serum |
| Li AM [ | China | Asian | 11.02 ± 3.36 | 10.55 ± 3.46 | NA | NA | 17.71 ± 20.80 | NA | 47 | 95 | Serum |
| Smith DF(mild) [ | America | Caucasian | 9.6 ± 2.5 | 9.7 ± 2.5 | 20.7 ± 4.6 | 19.4 ± 4.4 | 3.5 ± 1.1 | 0.4 ± 0.3 | 23 | 90 | Plasma |
| Smith DF(moderate to severe) [ | America | Caucasian | 9.0 ± 2.7 | 9.7 ± 2.5 | 23.4 ± 13.5 | 19.4 ± 4.4 | 15.2 ± 11.7 | 0.4 ± 0.3 | 42 | 90 | Plasma |
| Hirsch D [ | Australia | Caucasian | 10.0 ± 1.7 | 10.7 ± 1.2 | NA | NA | 12.1 ± 10.7 | NA | 23 | 17 | Serum |
| Chen VG [ | Brazil | Latino | 7.5 ± 1.5 | 8.5 ± 1.4 | NA | NA | NA | NA | 17 | 17 | Tonsil tissue |
| Wang W [ | China | Asian | 6.58 ± 0.61 | 5.69 ± 0.78 | 21.61 ± 2.28 | 18.98 ± 1.74 | 33.49 ± 5.6 | 1.16 ± 0.22 | 22 | 20 | Plasma |
Figure 2.Forest plot of random-effects analysis of IL-8 levels in the overall patients
Figure 3.Meta-analysis for the association between serum IL-8 levels and OSAS: subgroup analysis by age
Subgroup analysis for serum and plasma levels of interleukin-8
| Categories | Subgroup analysis | SMD (95%CI) | p-Value | I2 | Ph | meta-analysis model |
|---|---|---|---|---|---|---|
| Serum level | Overall | 0.915(0.418,1.411) | <0.001 | 96.9% | <0.001 | Random‐effects model |
| Age | ||||||
| Children | 0.445(0.214,0.689) | 0.01 | 0% | 0.646 | Fixed‐effect model | |
| Adult | 1.013(0.437,1.587) | <0.001 | 97.2% | <0.001 | Random‐effects model | |
| Ethnicity | ||||||
| Asian | 1.573(0.240,2.905) | 0.021 | 98.6% | <0.001 | Random‐effects model | |
| Caucasian | 0.558(0.237,0.877) | 0.001 | 87.7% | <0.001 | Random‐effects model | |
| Mean BMI (kg/m2) | ||||||
| ≤30 | 1.137(0.429,1.844) | <0.001 | 98.0% | <0.001 | Random‐effects model | |
| >30 | 0.568(0.052,1.084) | 0.031 | 87.5% | <0.001 | Random‐effects model | |
| Mean AHI (events/h) | ||||||
| ≤30 | 0.275(0.077,0.473) | 0.007 | 67.1% | <0.001 | Random‐effects model | |
| >30 | 2.064(0.791,3.337) | 0.001 | 98.4% | <0.001 | Random‐effects model | |
| Total number of participants | ||||||
| >100 | 1.883(0.925,2.841) | <0.001 | 98.8% | <0.001 | Random‐effects model | |
| ≤100 | 0.461(−0.020,0.950) | 0.064 | 90.1% | <0.001 | Random‐effects model | |
| Plasma level | Overall | 0.748(0.308,1.189) | 0.001 | 82.3% | <0.001 | Random‐effects model |
| Age | ||||||
| Children | 0.440(0.120,0.760) | 0.007 | 58.4% | 0.048 | Random‐effects model | |
| Adult | 1.832(0.521,3.144) | 0.006 | 91.0% | <0.001 | Random‐effects model | |
| Ethnicity | ||||||
| Asian | NA | NA | NA | NA | ||
| Caucasian | 0.837(0.345,1.328) | 0.001 | 84.2% | <0.001 | Random‐effects model | |
| Mean BMI (kg/m2) | ||||||
| ≤30 | 0.589(0.177,1.001) | 0.005 | 79.7% | <0.001 | Random‐effects model | |
| >30 | NA | NA | NA | NA | ||
| Mean AHI (events/h) | ||||||
| ≤30 | 0.660(0.297,1.022) | <0.001 | 39.3% | 0.193 | Random‐effects model | |
| >30 | 0.936(0.240,1.631) | 0.008 | 87.4% | <0.001 | Random‐effects model |
Figure 4.Meta-analysis for the association between serum IL-8 levels and OSAS: subgroup analysis by mean BMI
Figure 5.Meta-analysis for the association between serum IL-8 levels and OSAS: subgroup analysis by ethnicity
Figure 6.Meta-analysis for the association between serum IL-8 levels and OSAS: subgroup analysis by total number of participants
Figure 7.Meta-analysis for the association between serum IL-8 levels and OSAS: subgroup analysis by mean AHI
Meta-regression analysis of variables predicting serum and plasma levels of IL-8
| Age | R | Adjusted R2 | p |
|---|---|---|---|
| Serum | 0.696 | −0.049 | 0.749 |
| Plasma | 1.463 | 0.019 | 0.24 |
| Mean BMI of OSAS | R | Adjusted R2 | p |
| Serum | −1.21 | 0.005 | 0.347 |
| Plasma | 1.775 | 0.952 | 0.205 |
| Mean AHI of OSAS | R | Adjusted R2 | p |
| Serum | 0.657 | 0.003 | 0.308 |
| Plasma | 0.691 | 0.404 | 0.625 |
| Ethnicity | R | Adjusted R2 | p |
| Serum | 0.458 | −0.029 | 0.495 |
| Plasma | −0.987 | −0.352 | 0.638 |
| Number of participants | R | Adjusted R2 | p |
| Serum | 1.657 | 0.029 | 0.208 |
| Plasma | NA | NA | NA |
| Author | Selection | Comparability | Exposure | Score | |||||
|---|---|---|---|---|---|---|---|---|---|
| Case definition | Representativeness | Control selection | Control definition | Comparability in the design/statistical analysis of case and control | Ascertainment of exposure | Same method of ascertainment for cases and controls | Non-Response rate | ||
| Ohga E [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Alzoghaibi [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Ryan S [ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| Devouassoux G [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Borel JC [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Carpagnano GE [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Kim J [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Bouloukaki I [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Wang Y [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Thunstrom E [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Archontogeorgis K [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Taillé C [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Vicente E [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Jin F [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Santamaria-Martos F [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Ming H [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Zhang D [ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| Bhatt SP [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Bilal N [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Tam CS [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Li AM [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Smith DF [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Hirsch D [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Chen VG [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Wang W [ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |